Algernon Pharmaceuticals Inc.
AGNPFOTCHealthcare● Active
$0.44
+$0.01(+1.27%)
Market Cap$1540220
P/E Ratio—
52W High$0.713
52W Low$0.23
Algernon Pharmaceuticals Inc. (AGNPF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AGNPF · as of 2026-06-15
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-08 | 2024-08 | 2023-08 | 2022-08 | 2021-08 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | $0.00B | ($0.00B) | ($0.00B) | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.00B | $0.00B | $0.01B | $0.01B | $0.01B |
| Operating Income | ($0.00B) | ($0.00B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.00B) | ($0.00B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.00B) | ($0.00B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.58 | $-0.25 | $-4.50 | $-8.70 | $-12.40 |
| Wtd Avg Shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| EBITDA | ($0.00B) | ($0.00B) | ($0.00B) | ($0.01B) | ($0.01B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-15 · CAD · B
Explore more Algernon Pharmaceuticals Inc. data
About Algernon Pharmaceuticals Inc. (AGNPF) Income Statement
Algernon Pharmaceuticals Inc. (AGNPF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, AGNPF reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.00B) — a net profit margin of —.
Frequently asked questions
AGNPF · 4 questionsAlgernon Pharmaceuticals Inc. (AGNPF) reported revenue of $0.00B for 2025, down —% year-over-year.
AGNPF revenueAGNPF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-15